Long-term Safety of Avoralstat in Hereditary Angioedema

Phase 3, open-label, single-arm trial of avoralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Proportion of subjects who discontinue due to a treatment-emergent adverse event, who experience a treatment-emergent serious AE, who experience a Grade 3 or 4 AE and who experience Grade 3 or 4… up to 72 weeks. Started Dec 2015; status: terminated.